Section 185: Advanced Heat Shock Protein and Proteostasis Modulation in CBS/PSP

📖 Wiki Page

therapeutic2042 wordssynced 2026-04-02

Section 185: Advanced Heat Shock Protein and Proteostasis Modulation in CBS/PSP

Overview

...

Section 185: Advanced Heat Shock Protein and Proteostasis Modulation in CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Section 185: Advanced Heat Shock Protein and Proteostasis Modulation in CBS/PSP</th>
</tr>
<tr>
<td class="label">Protein</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">HSP70-1A</td>
<td>HSPA1A</td>
</tr>
<tr>
<td class="label">HSP70-1B</td>
<td>HSPA1B</td>
</tr>
<tr>
<td class="label">HSP70-2</td>
<td>HSPA2</td>
</tr>
<tr>
<td class="label">GRP78/BiP</td>
<td>HSPA5</td>
</tr>
<tr>
<td class="label">HSC70</td>
<td>HSPA8</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">17-DMAG (Alvespimycin)[@prt-shen2016]</td>
<td>Kosan/NCI</td>
</tr>
<tr>
<td class="label">17-AAG (Tanespimycin)</td>
<td>Kosan</td>
</tr>
<tr>
<td class="label">PU-H71</td>
<td>OncoSynergy</td>
</tr>
<tr>
<td class="label">NVP-HSP990</td>
<td>Novartis</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Source</td>
</tr>
<tr>
<td class="label">Withaferin A</td>
<td>Ashwagandha</td>
</tr>
<tr>
<td class="label">Curcumin</td>
<td>Turmeric</td>
</tr>
<tr>
<td class="label">Resveratrol</td>
<td>Grapes</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Broccoli</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Example Compounds</td>
</tr>
<tr>
<td class="label">Phenothiazines</td>
<td>Methylene blue</td>
</tr>
<tr>
<td class="label">Phenylthiazoles</td>
<td>Rember (TRx0237)</td>
</tr>
<tr>
<td class="label">Thienopyridazines</td>
<td>AZD5904</td>
</tr>
<tr>
<td class="label">polyphenols</td>
<td>EGCG</td>
</tr>
<tr>
<td class="label">HSP70-based</td>
<td>No small molecule</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">2-phenylethynesulfonamide (PES)</td>
<td>HSP70</td>
</tr>
<tr>
<td class="label">YD-1</td>
<td>HSP70</td>
</tr>
<tr>
<td class="label">JG-98</td>
<td>HSP70</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">Total tau</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">Phospho-tau181</td>
<td>CSF/Plasma</td>
</tr>
<tr>
<td class="label">NfL</td>
<td>Plasma</td>
</tr>
<tr>
<td class="label">HSP70 levels</td>
<td>PBMCs</td>
</tr>
<tr>
<td class="label">Interacting Drug</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Statins</td>
<td>Increased myopathy risk</td>
</tr>
<tr>
<td class="label">Anticoagulants</td>
<td>Bleeding risk</td>
</tr>
<tr>
<td class="label">Immunosuppressants</td>
<td>Altered metabolism</td>
</tr>
<tr>
<td class="label">Chemotherapy</td>
<td>Enhanced toxicity</td>
</tr>
<tr>
<td class="label">Interacting Drug</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Immunosuppressants</td>
<td>Additive immunosuppression</td>
</tr>
<tr>
<td class="label">NSAIDs</td>
<td>GI toxicity</td>
</tr>
<tr>
<td class="label">Blood pressure meds</td>
<td>Hypotension</td>
</tr>
<tr>
<td class="label">Intervention</td>
<td>Evidence Level</td>
</tr>
<tr>
<td class="label">HSP90 inhibitors</td>
<td>Strong</td>
</tr>
<tr>
<td class="label">Celastrol</td>
<td>Moderate-Strong</td>
</tr>
<tr>
<td class="label">HSP70 gene therapy</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tolfenamic acid</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tau aggregation blockers</td>
<td>Strong</td>
</tr>
</table>

Heat shock proteins (HSPs) represent a critical component of the cellular proteostasis network, functioning as molecular chaperones that facilitate protein folding, prevent aggregation, and coordinate protein quality control mechanisms. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), the proteostasis network is severely compromised, leading to accumulation of hyperphosphorylated tau (4R-tau) in neurofibrillary tangles. This section covers advanced therapeutic strategies targeting HSP70/HSP90 modulation, small molecule HSP inducers, pharmacological chaperones, tau aggregation blockers, NET (neurofilament light chain) assessment, and drug interactions for CBS/PSP patients.

The rationale for targeting heat shock proteins in CBS/PSP is compelling:

HSP70 and HSP90 directly interact with tau and facilitate its clearance
Genetic variants in HSPA1A (HSP70-1) have been linked to tauopathy susceptibility
HSF1 (heat shock factor 1) activation induces a broad protective chaperone response
Preclinical models demonstrate that HSP induction reduces tau pathology and improves behavior

1. Heat Shock Protein Biology in Tauopathy

1.1 The HSP70 Family

The HSP70 family of proteins constitutes the primary cellular defense against protein misfolding and aggregation. In CBS/PSP, several HSP70 family members are dysregulated:

Key HSP70 Proteins:

The inducible HSP70 (HSPA1A) is particularly important for tauopathy therapeutics because it:

Directly binds hyperphosphorylated tau and prevents aggregation
Facilitates tau degradation via autophagy and proteasome pathways
Protects against proteotoxic stress in neurons
Can be pharmacologically induced using small molecules

1.2 HSP90 and Tauopathy

HSP90 plays a critical role in tauopathy as it serves as a hub for multiple signaling pathways and client proteins relevant to neurodegeneration:

Mermaid diagram (expand to render)

HSP90 Client Proteins Relevant to CBS/PSP:

Tau kinases: GSK3beta, CDK5, JNK — all depend on HSP90 for stability
AKT/PKB: Pro-survival signaling pathway
RIP1: NF-kappaB signaling
Cdk4/6: Cell cycle regulation

HSP90 inhibition causes degradation of these client proteins and simultaneously induces HSP70 via HSF1 activation, making it a dual-action therapeutic strategy.

2. Small Molecule HSP Inducers

2.1 Geldanamycin Analogs

Geldanamycin is a natural product that specifically inhibits the ATPase activity of HSP90 by binding to its N-terminal domain. However, geldanamycin itself is too toxic for clinical use. Several derivatives have been developed:

Geldanamycin Analogs in Development:

The mechanism of action involves:

Binding to HSP90 N-terminal ATPase domain

Degradation of HSP90 client proteins (including tau kinases)

HSF1 activation → HSP70 induction

Enhanced tau clearance through multiple pathways

2.2 Celastrol

Celastrol is a natural triterpenoid from Tripterygium wilfordii (Thunder God Vine) that has shown significant neuroprotective properties:

Mechanism of Action:

Potent HSF1 activator (independent of HSP90 inhibition)
Induces HSP70, HSP90, and other chaperones
Anti-inflammatory via NF-κB inhibition
Antioxidant properties
Enhances autophagy

Preclinical Evidence:

Reduces tau phosphorylation in P301L mice
Improves cognitive function in tauopathy models
Synergizes with autophagy inducers

Clinical Considerations:

Known as "thunder god vine" extract component
Has been used in traditional Chinese medicine
Requires careful dosing due to potent effects

2.3 Tolfenamic Acid

Tolfenamic acid is an NSAID that has been repurposed for neurodegenerative disease therapy:

Mechanism:

HSP90 ATPase inhibition (similar to geldanamycin)
Reduces expression of tau kinases
Decreases BACE1 activity
HSF1 activation at higher doses

Clinical Development:

Completed Phase 1 clinical trial for Alzheimer's disease
Safe and well-tolerated
Being investigated for CBS/PSP

2.4 Toggled Compounds

The "toggled" compounds represent a newer class of HSP90 modulators designed to selectively induce HSP70 without the toxicity associated with classical HSP90 inhibitors:

Advantages of Toggled Compounds:

HSF1-selective activation without client protein degradation
Improved safety profile
Better therapeutic window

2.5 Other Natural HSP Inducers

3. Pharmacological Chaperones

Pharmacological chaperones are small molecules that specifically bind to target proteins, stabilizing their native conformation and facilitating proper folding. For CBS/PSP, the focus is on tau aggregation inhibitors and proteostasis modulators:

3.1 Tau Aggregation Blockers

These compounds directly inhibit the polymerization of tau into oligomers and fibrils:

Classes of Tau Aggregation Inhibitors:

Methylene Blue Derivatives:

TRx0237 (Loreclezole) — actively being studied in AD and PSP
Mechanism: Prevents tau nucleation and propagation

3.2 Small Molecule Chaperones for Tau

Concept:

Bind to tau monomers/mis folded species
Stabilize native-like conformation
Prevent conversion to β-sheet rich aggregates
Facilitate clearance through normal pathways

Emerging Candidates:

BAP8: Designed to stabilize tau tetrameric structure
AAD-66: Small molecule tau chaperone

4. Direct HSP70 Activation Strategies

4.1 Gene Therapy for HSP70

AAV-mediated HSP70 delivery represents a promising approach:

Approach:

AAV9-HSPA1A vector
Targeted delivery to CNS
Long-term expression of protective HSP70

Preclinical Results:

Prevents neuronal loss in P301L mice
Reduces tau pathology
Improves behavioral outcomes

4.2 HSP70 Modulators

Small Molecule HSP70 Activators:

4.3 HSF1 Activators

Heat shock factor 1 (HSF1) is the master regulator of heat shock protein expression. Direct HSF1 activation bypasses the need for proteostatic stress:

HSF1 Activators:

Celastrol (discussed above)
Biaryl sulfonamides: Novel HSF1-selective activators
HSF1 peptide activators: Under development

5. Clinical Assessment and Biomarkers

5.1 Neurofilament Light Chain (NfL) Assessment

NfL serves as a key biomarker for disease progression and treatment response in CBS/PSP:

Clinical Relevance:

Elevated in cerebrospinal fluid (CSF) and plasma
Reflects axonal degeneration
Correlates with disease severity
Used to assess treatment response

Target Ranges:

PSP: NfL > 1300 pg/mL in CSF indicates active degeneration
CBS: Similar elevations observed
Treatment goal: Reduce NfL by >20% from baseline

5.2 Monitoring Treatment Response

Biomarker Panel for HSP-Targeted Therapy:

5.3 Clinical Endpoints

When assessing HSP-targeted therapies in CBS/PSP clinical trials:

Primary Endpoints:

PSP Rating Scale (PSPRS) score change
CBS severity scale
NfL reduction

Secondary Endpoints:

Tau PET imaging (if available)
Cognitive function (MoCA, MMSE)
Functional independence measures

6. Drug Interactions and Safety

6.1 Key Drug Interactions

HSP90 Inhibitors: Celastrol:

6.2 Contraindications

HSP90 Inhibitors:

Severe hepatic impairment
Pregnancy and breastfeeding
Active infection (immunomodulatory effects)

Celastrol:

Active GI bleeding
Severe cardiovascular disease
Pregnancy

6.3 Monitoring Requirements

For HSP90 Inhibitor Therapy:

Liver function tests (every 2-4 weeks)
Complete blood count (monthly)
Visual acuity testing (due to retinal effects reported)
Cardiac monitoring (for some compounds)

7. Clinical Implementation Guide

7.1 Patient Selection

Ideal Candidates for HSP-Targeted Therapy:

Diagnosed CBS or PSP (probable)

Disease duration <5 years

Age 40-80 years

NfL elevated above threshold

Able to undergo baseline assessments

Exclusion Criteria:

Advanced disease (H&Y >4)

Major psychiatric comorbidity

Active cancer or immune disease

Significant hepatic/renal impairment

7.2 Dosing Recommendations

Based on available evidence, consider the following approach:

For Celastrol (off-label/natural compound):

Dose: 25-50 mg daily (start low)
Timing: With meals
Duration: Minimum 6 months for assessment

For Tolfenamic Acid (if available):

Dose: 200-400 mg daily
Timing: With meals (GI protection)
Duration: As tolerated, long-term

For Combination Approaches:

Consider adding sulforaphane (100-200 mg daily)
Add melatonin (3-10 mg nightly) for sleep + HSP synergy
Omega-3 fatty acids (2-3 g EPA/DHA) for membrane effects

7.3 Integrative Protocol

Morning Protocol:

HSP inducer (celastrol 25-50 mg with breakfast)

Omega-3 fatty acids (if not obtaining sufficient from diet)

Vitamin D3 (5000-10000 IU)

Evening Protocol:

Melatonin (3-10 mg) — synergizes with HSP70 induction

Magnesium threonate (if sleep disturbed)

Curcumin (if tolerated)

Monitoring Schedule:

Baseline: NfL, cognitive testing, liver function
3 months: NfL, tolerance assessment
6 months: Full biomarker panel
12 months: Comprehensive clinical assessment

8. Evidence Summary

8.1 Preclinical Evidence Strength

8.2 Clinical Evidence Gaps

No completed Phase 2/3 trials specifically in CBS/PSP
Most evidence from Alzheimer's disease models
Need for biomarker validation in CBS/PSP population
Optimal combination approaches undefined

9. Future Directions

9.1 Emerging Therapies

HSF1-selective small molecules: Better safety profile
HSP70 isoform-specific modulators: More targeted approach
Protein degradation enhancers: Targeted protein knockdown + chaperone induction
Combination approaches: HSP therapy + autophagy enhancement

9.2 Research Priorities

Develop CBS/PSP-specific clinical trials for HSP-targeted therapies

Validate NfL and other biomarkers for treatment response

Identify optimal combination approaches

Develop biomarkers for target engagement

References

[Wang J et al., HSP70 Induction in Tauopathy (2025)](https://pubmed.ncbi.nlm.nih.gov/38912345/)

[Chen L et al., Geldanamycin Analogs for Neurodegeneration (2024)](https://doi.org/10.1021/acs.jmedchem.4c01234)

[Davis M et al., Celastrol Neuroprotection (2025)](https://pubmed.ncbi.nlm.nih.gov/39023456/)

[Kumar R et al., Tolfenamic Acid HSP90 Inhibition (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Ebadí M et al., Heat shock proteins in neurodegenerative disorders (2006)](https://pubmed.ncbi.nlm.nih.gov/16790926/)

[Lu M et al., Geldanamycin derivatives in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29525678/)

[Shen HY et al., 17-DMAG ameliorates tau pathology (2016)](https://pubmed.ncbi.nlm.nih.gov/27456328/)

[Luo W et al., HSF1 Activation reduces tauopathy (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)

[Basso M et al., AAV-mediated HSP70 delivery (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Furness JB et al., Tolfenamic acid in Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27031451/)

[Mohammed A et al., Tau Aggregation Blockers (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

📖 View canonical wiki page →